Pilot Text Message for Influenza Vaccination

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Melissa Stockwell, MD, MPH, Columbia University
ClinicalTrials.gov Identifier:
NCT01761734
First received: December 30, 2012
Last updated: June 22, 2014
Last verified: June 2014
  Purpose

Influenza is an important and potentially preventable cause of morbidity and mortality, yet only 46% of U.S. adults were vaccinated by the end of the 2011-12 influenza season despite influenza vaccination being widely recommended, effective, and safe. Influenza vaccination rates are even lower in racial/ethnic minority groups. In order to address the problem of low influenza vaccination rates in minority adults, we plan to build on the well-accepted practice of immunization recall-reminders and the emerging practice of using text message to pilot the feasibility of using text messaging to improve influenza vaccination coverage rates in a low health literacy, largely minority, publicly insured adult population.


Condition Intervention
Influenza
Behavioral: text message

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Pilot Study of Text Message Reminders for Flu Vaccine For Adults

Resource links provided by NLM:


Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Receipt of an influenza vaccine dose [ Time Frame: March 31, 2013 ] [ Designated as safety issue: No ]
    Proportion of individuals in each group receiving an influenza dose by the end of the influenza season


Enrollment: 1000
Study Start Date: January 2013
Study Completion Date: May 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: text message
receipt of text message
Behavioral: text message
No Intervention: usual care
usual care

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • > or = 18 years of age,
  • at least one visit to the AIM clinic during the previous year
  • a cell phone number in the registration system
  • fluent in English or Spanish. Exclusion criteria

Exclusion Criteria:

  • Receipt of influenza vaccination during the 2012-2013 influenza season prior to randomization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01761734

Locations
United States, New York
Columbia University
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Investigators
Principal Investigator: Melissa Stockwell, MD MPH Columbia University
Principal Investigator: Steven Shea, MD MS Columbia University
Principal Investigator: Jessica Singer, MD MPH Columbia University
  More Information

No publications provided

Responsible Party: Melissa Stockwell, MD, MPH, Assistant Professor of Pediatrics and Population and Family Health, Columbia University
ClinicalTrials.gov Identifier: NCT01761734     History of Changes
Other Study ID Numbers: AAAK5058
Study First Received: December 30, 2012
Last Updated: June 22, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Columbia University:
Influenza vaccination

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on July 29, 2014